| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |